Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has announced its participation in four major investor conferences this September. The company's leadership team, including CEO Kyle Gano, CFO Matt Abernethy, and other executives, will present at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and TD Cowen Novel Mechanisms Summit.
The presentations will be accessible via live webcasts on Neurocrine's website, with replays available for approximately one month. The company specializes in developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 8:00 a.m. ET. CEO Kyle Gano and VP of Investor Relations Todd Tushla will represent the company at the event.
The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for approximately one month after the event. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various neurological conditions, including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (NASDAQ:NBIX) reported strong Q2 2025 financial results with total net product sales of $682 million, representing 17% year-over-year growth. INGREZZA achieved Q2 net product sales of $624 million, while CRENESSITY contributed $53 million with 664 new patient enrollment start forms.
The company narrowed its 2025 INGREZZA net product sales guidance to $2.5-$2.55 billion from $2.5-$2.6 billion. Q2 GAAP net income was $107.5 million ($1.06 per share), compared to $65 million ($0.63 per share) in Q2 2024. The company maintains a strong balance sheet with $1.8 billion in cash and marketable securities.
Key developments include initiating Phase 3 trials for NBI-'568 in schizophrenia and advancing the pipeline in neuropsychiatry. The company has repurchased $168 million of common stock under its $500 million share repurchase program.
Neurocrine Biosciences (NASDAQ:NBIX) and PicnicHealth have revealed key findings from their CAHtalog® Registry study focused on congenital adrenal hyperplasia (CAH). The research, conducted in collaboration with the CARES Foundation, identified that CAH patients require continuous, lifelong adjustments to glucocorticoid dosing to maintain condition control.
The study leverages PicnicHealth's AI-powered technology to curate medical records and enable remote participation, overcoming traditional challenges in rare disease research. The technology allows for data collection from multiple care locations while providing patients with an intuitive app featuring an AI assistant for medical record navigation.
Additional findings regarding treatment patterns and condition progression were presented at ENDO 2025, demonstrating the registry's value in advancing understanding of this rare genetic condition affecting adrenal gland function.
Neurocrine Biosciences (NASDAQ: NBIX) presented new analysis from the CAHtalog® registry revealing significant challenges in managing classic congenital adrenal hyperplasia (CAH). The study found that approximately 95% of patients experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.
The analysis, presented at ENDO 2025, examined data from 98 patients (37 adults, 42 children/adolescents, 19 cross-age contributors) over a median period of 8.6 years. Among patients eligible for health state transition analysis, 88.9% experienced at least one health state change, with 58.7% undergoing three or more changes, highlighting the unpredictable nature of disease control.
The findings emphasize the limitations of current glucocorticoid therapy and demonstrate the need for alternative treatment approaches for managing CAH effectively.
Neurocrine Biosciences (NASDAQ: NBIX) presented one-year data from Phase 3 CAHtalyst™ studies demonstrating CRENESSITY® (crinecerfont) improved weight-related outcomes in classic congenital adrenal hyperplasia patients. The studies, involving 103 pediatric and 182 adult patients, showed significant improvements in body mass index (BMI) and insulin resistance.
Key findings include: 27% of adults achieved >5% weight reduction by Month 12 in the continuous CRENESSITY group, while 27% of pediatric patients achieved ≥0.2 reduction in BMI SDS. Substantial improvements in insulin resistance (HOMA-IR) were observed in both adult and pediatric patients through one year of treatment.
The treatment demonstrated a favorable safety profile, with mostly mild to moderate side effects that were generally temporary and did not lead to discontinuation.
Neurocrine Biosciences (NASDAQ: NBIX) presented one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) at ENDO 2025. The Phase 3 trial, involving 182 adult patients aged 18-58, demonstrated sustained efficacy in treating classic congenital adrenal hyperplasia (CAH).
Key findings include 25-30% reduction in glucocorticoid doses while maintaining or improving androstenedione levels. The study showed improvements in insulin resistance and hirsutism in female participants. CRENESSITY demonstrated a favorable safety profile, with headache and fatigue as the most common side effects, mostly mild to moderate and temporary.
The data complements previously reported pediatric results and reinforces CRENESSITY's role in CAH management by effectively controlling ACTH and adrenal steroid imbalances while enabling lower, more physiologic steroid dosing.
Neurocrine Biosciences (NASDAQ: NBIX) has scheduled its second quarter 2025 financial results conference call and webcast for July 30, 2025, at 1:30 p.m. Pacific Time. The company will release its Q2 2025 financial results at 1:00 p.m. PT on the same day.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for multiple conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a diverse pipeline with several compounds in mid to late-phase clinical development.
Neurocrine Biosciences (Nasdaq: NBIX) has initiated a Phase 1 first-in-human clinical study for NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor (CRF1) antagonist. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy adult participants.
NBIP-01435 is administered via subcutaneous injection and is being developed for the treatment of congenital adrenal hyperplasia (CAH), a rare genetic condition affecting adrenal steroid hormone production. This represents the company's first investigational peptide from its biologics pipeline to enter clinical trials.
The development builds on Neurocrine's existing presence in CAH treatment, following the FDA approval of crinecerfont in December 2024, which was the first new CAH treatment in 70 years. NBIP-01435 originated from a research collaboration with Sentia Medical Sciences, Inc., initiated in April 2021, for which Neurocrine holds exclusive development and commercialization rights.
Neurocrine Biosciences (NASDAQ:NBIX) announced new post-hoc data analyses from the KINECT-HD study showing that INGREZZA (valbenazine) significantly reduced both cognitive and motor-related disease burden in Huntington's disease chorea patients compared to placebo.
The 12-week Phase 3 trial demonstrated statistically significant improvements (p<0.05) across multiple measures. Key cognitive improvements included reduced memory loss (-0.9 vs -0.2), better decision-making abilities (-1.0 vs -0.3), and improved word-finding (-0.9 vs -0.3). Motor improvements included enhanced mobility (-0.9 vs -0.2), reduced abnormal movements (-1.5 vs -0.8), and better swallowing (-1.0 vs -0.3).
These findings represent the first clinical study demonstrating measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor in Huntington's disease chorea patients.